Functional gene disruption is a central tenet of cancer research, where novel drug targets are often identified and validated through cell-growth based knockdown studies or screens. Short hairpin RNA (shRNA)-mediated mRNA knockdown is widely used in both academic and pharmaceutical settings. However, off-target effects of shRNAs as well as interference with endogenous small RNA processing have been reported [1] [2] [3] . We show here that lentiviral delivery of both gene-specific and non-targeting control shRNAs impair in vitro cell growth in a sequence independent manner. In addition, exogenous shRNAs induce a depressed cell-cycle-gene expression signature that is also shRNA-sequence independent and present across several studies. Further, we observe an shRNA mediated general repression of microRNAs belonging to polycistronic genetic clusters, including microRNAs from established oncogenic microRNA clusters. The collective impact of these observations is particularly relevant for cancer research, given the widespread historical use of shRNAs and the common goal of interrogating genes that regulate proliferation. We therefore recommend that when employing shRNA for target validation, care be taken to titrate shRNA dose, use hairpin-expressing controls, perform gene-of-interest rescue experiments and/or corroborate shRNA-derived results by small interfering RNA (siRNA) knockdown or CRISPR/Cas9-mediated genetic knockout. Minimizing these deleterious sequence independent effects will improve research fidelity and help address reported challenges in experimental reproducibility 4 .
Gene-targeting shRNAs are typically introduced into cell lines in vitro through lentiviral infection, leading to genomic integration and permanent expression of the hairpin construct. Functionally similar to siRNAs, which are directly loaded into the RISC complex, shRNA must first be transcribed and processed by cellular microRNA biogenesis machinery. ShRNAs are valued because they are easy to use and can affect long term knockdown of a gene, whereas siRNA knockdown is transient. CRISPR/Cas9-mediated knockout also results in a permanent genetic event, though in some cases knockdown studies are preferred to evaluate intermediate gene expression phenotypes and avoid severe phenotypes or lethality due to complete loss of gene function. While shRNA knockdown occupies an important niche between short term and permanent gene disruption, their use comes with caveats. In addition to off-target effects and impact on small RNA processing machinery, shRNA-induced liver and neuronal toxicity have been documented in vivo 3, 5 . In addition, shRNA-mediated cytotoxicity has been implicated in MYCdriven hepatocellular carcinoma in mice 6 .
In our recent work on the role of LIN28B and its microRNA target let-7 in neuroblastoma we described a reduced-growth phenotype produced by shRNA-mediated LIN28B knockdown that was not replicated by either siRNA or CRISPR/Cas9-mediated LIN28B knockout 7 . To further explore this observed shRNA induced toxicity, we first compared the effects of shRNA-and siRNA-mediated LIN28B knockdown on the cell cycle profile of BE(2)C neuroblastoma cells (Fig.  1a, b) . We observed disturbed profiles in both non-targeting control and LIN28B-targeting shRNA infected cells (Fig. 1c) . This effect was not observed in control or LIN28B-siRNA transfected cells, consistent with our previous work (Fig. 1d) . MYCN-siRNA served a control for an altered cell cycle profile (Fig. 1d) . We next tested this shRNA/siRNA relationship in K562 cells, a morphologically distinct leukemia cell line that also expresses LIN28B, and again observed that multiple LIN28B-targeting shRNAs reduced cell growth similar to the ABL1 siRNA control, while two LIN28B-targeting siRNAs did not (Fig. 1e, f) . We observed a similar pattern of shRNA, but not siRNA, induced growth impairment during the course of studies of the NAT10 acetyltransferase in BE(2)C cells (Supp. Fig. 1a, b) . LIN28B has recently been implicated in pancreatic cancer, where pancreatic cell growth inhibition was demonstrated using LIN28B-specific shRNAs 8 . However, we observed that the same pancreatic cancer cell lines were entirely refractory to complete LIN28B protein loss mediated by CRISPR/Cas9 targeting of the LIN28B genetic locus with multiple sgRNAs (Supp. Fig. 2a, b) . Together, these results suggest that exogenous shRNA expression may generally suppress cell growth independent of hairpin sequence, potentially leading to misleading experimental conclusions. Of note is the observation that the non-targeting control hairpin induced the same cell cycle defect as gene-targeting shRNAs (Fig. 1c) .
To further understand the apparent sequence independent growth inhibition of shRNAs, we interrogated the effect of a panel of scrambled siRNA, GFP-targeting CRISPR/Cas9, and nontargeting shRNA controls on the growth of BE(2)C and HeLa cells five days post treatment. This approach allowed us to test each platform for effects on proliferation that were independent of unintentional gene targeting side effects. We intentionally used a high concentration of siRNA (100nM), as well as an siRNA against RPL3, a target well documented to impair cell proliferation 9 as a positive control for reduced cell growth. Multiplicity of infection (MOI) for lentiviral CRISPR/Cas9 and shRNA constructs ranged from low MOIs of 1 to high MOIs of 20. Neither scrambled sequence control siRNAs displayed growth abnormalities, similar to the mocktransfection, whereas the RPL3-targeting siRNA severely impaired cell growth in both cell types, as expected (Fig. 2a,b ). Cas9 and Cas9/GFP-targeting-sgRNA infected cells responded similarly, with neither construct perturbing growth compared to mock-infection, regardless of MOI. In contrast, scrambled sequence shRNA-expressing lentiviruses significantly reduced both BE(2)C and HeLa cell proliferation over the 5 day experiment, in a dose-dependent manner at MOIs of 10 and 20 (Fig. 2a, b) .
We sought to gain insight into the observed sequence non-specific shRNA induced proliferative defect and performed global mRNA expression analysis on BE(2)C cells infected with empty lentivirus, non-targeting control shRNA, or each of three LIN28B targeting shRNAs. Replicate samples showed high correlation within each condition (Fig. 3a) . Given the proliferation phenotype driven by shRNAs, we first identified the cell cycle genes that were differentially regulated after shRNA transduction and noted that all four shRNA samples, again including the non-targeting control, displayed significant down regulation of cell cycle genes compared to empty vector (Fig. 3b) . Furthermore, the most significantly effected Gene Ontology processes were almost universally cell cycle related in all four shRNA samples (Fig. 3c) . These data are consistent with a model wherein high level exogenous shRNA expression has a sequence-independent effect on cell proliferation as demonstrated by consistent growth impairment and downregulation of cell cycle related processes (Fig. 2, Fig. 3c) .
We compared our expression data to two existing shRNA-based microarray datasets; one from BE(2)C neuroblastoma cells and the other from DU145 prostate cancer cells 10, 11 . Correlative analysis within the two studies showed agreement within sample replicates (Supp. Fig. 3a, 4a) . Differential gene expression analysis showed a preferential down-regulation of cell cycle genes, consistent with our own data (Supp. Fig. 3b, 4b) . Gene Ontology analysis of the most significantly altered pathways also revealed a strong cell cycle signature in both datasets ( Supp Fig, 3c, 4c) .
Indeed, Venn diagram overlap of downregulated Gene Ontology processes revealed 44 common to all the three datasets ( Fig. 3d ; Supp. Table 1 ). Of note, 42 of them were cell cycle processes. Moreover, the 18 most highly significant for each comparison were all cell cycle-related and showed strong agreement across the studies. Note the agreement between our control-shRNA pattern and those of the other two studies (Fig. 3e) . These inter-study observations are consistent with our own data and support a model where small hairpin RNAs inhibit cell growth in a sequence-independent manner.
Following transcription, shRNAs are processed by the microRNA biogenesis machinery and have been reported to impact microRNA levels 3, 12, 13 . We therefore examined global microRNA expression in the same set of BE(2)C shRNA transduced cells. Analysis of microRNA expression patterns revealed high correlation among all of the shRNA samples, including the nontargeting scrambled sequence control shRNA, which was more closely correlated with LIN28B shRNA samples than empty vector control. This pattern is consistent with observed sequenceindependent effects on proliferation (Fig. 1, Supp. Fig. 1, Fig.4a ). Of the 50 most downregulated microRNAs in each sample set, 25 were consistent between control shRNA and all three LIN28B shRNA-expressing cells (Fig. 4b) . Upon analysis of these 25 microRNAs, we discovered that 24 of them belonged to clustered microRNA loci (Fig. 4c) . Moreover, when we examined expression of clustered vs. single-microRNA loci across the genome, we observed a strong global downregulation of clustered microRNA expression compared to singleton microRNAs (Fig. 4d) . These data indicated that the broad cell growth impairment observed following transduction of high levels of shRNA correlated markedly with aberrant processing of clustered species of microRNA.
The microRNAs of the miR-17, miR-18, miR-19, and miR-25 families are highly expressed in multiple cancers. They are established pro-growth oncogenes, and are all transcribed from one of three OncomiR clusters 14, 15 . Indeed, eight of these microRNAs are among the highest expressed microRNAs in BE(2)C cells (Supp. Fig. 5a ). The miR-17-92 cluster is the best characterized of these and has been identified as a transcriptional target of MYC 16 . Upon shRNA infection of BE(2)C cells, microRNA levels from the miR-17-92 OncomiR cluster were broadly suppressed in all shRNA samples, including non-targeting control shRNA (Fig. 4e) . Further, we observed the same pattern of repression in the remaining two OncomiR clusters (Supp Fig. 5c, d ). Given their importance in cancer biology, sequence-independent shRNA-induced suppression of these oncogenic microRNA clusters may offer a plausible explanation for the proliferative defects observed in our study.
Loss of gene function analysis is indispensable to cancer research. Within the Nature family of journals alone, chosen for analysis due to their high rate of depositing published manuscripts into pubmed central, there have been over three thousand publications in cancer research over the last ten years, well over a thousand of which have included gene knock-down data (Supp. Fig. 6a-c) . Tool fidelity in such a widely used research approach is therefore critical. We demonstrate here that shRNA can impact cell growth in vitro as well as preferentially disrupt clustered microRNA expression in a sequence-independent manner. We further identify a depressed cell cycle Gene Ontology signature that is consistent across multiple shRNA studies. Our data poses a significant concern for use of shRNA knockdown for cancer research in particular, where the common goal is to identify genes whose knock-down compromises cell growth. This is particularly true for easy-to-infect cells, which include most adherent lines. Difficultto-infect cells, such as lymphocytes, might be inherently amenable to shRNA use, due to their self-limitation of viral dose 17 . Indeed, Sigma-Aldrich manufacturer protocol suggests using and MOI of 1 to deliver shRNA virus to cells. When we infected BE(2)C cells with LIN28B shRNA virus below an MOI of 1, two out of three failed to efficiently knockdown LIN28B expression (Supp. Fig.  7 ). The challenge therefore is to titrate viral dose only as high as needed to achieve target suppression while remaining below cytotoxic levels.
To address the shortcomings of small hairpin RNAs and to reduce potential contributions to irreproducibility in cancer research, we recommend the following practices for shRNA use. Care should be taken to titer viral supernatants, followed by use of the lowest MOI possible to effectively knockdown the gene of interest. Non-targeting scrambled sequence hairpin controls should always be used at similar MOI to control for the sequence-independent effects reported in this manuscript. An additional empty vector control should also be used to control for general effects of shRNA expression. Finally, phenotypes observed through effective use of shRNA knockdown should be reverted by expression of shRNA-resistant versions of the gene of interest and/or validated by either siRNA or CRISPR/Cas9 use (Supp. Fig. 6d, 8) .
Reproducibility is central to scientific advancement, but has been difficult to achieve in recent years, especially in the field of cancer research 4, 18 . Research tools such as exogenous shRNA that inappropriately effect the same cell growth inhibition that is frequently the goal of target validation studies in cancer research have almost certainly contributed, despite good faith efforts of the researchers involved. Minimizing shRNA-induced, sequence independent detrimental effects on cell growth and expression signatures will reduce false positive results and contribute to improved reproducibility in cancer and potentially other research fields.
Materials and Methods:
Cell Culture: BE(2)C (ATCC CRL-2268), HeLa (ATCC CCL-2), and K562 (ATC CCL-243) were maintained in RPMI media with 10% heat-inactivated fetal calf serum, 1 µg ml−1 penicillin, and 1 U ml−1 streptomycin. All cell lines were purchased for the purposes of this study, are not among commonly misidentified cell lines (according to the International Cell Line Authentication Committee), and tested negative for mycoplasma contamination.
siRNA: siRNA transfections were performed with Lipofectamine™ RNAiMAX Transfection Reagent as per the manufacturer protocol. siRNAs used: siCon/Con1 (ThermoFisher cat# 4390843); siCon2 (ThermoFisher cat# 4390846); siLIN28B (ThermoFisher cat# 4392420, identifier s52477); siMYCN (ThermoFisher cat# 4392420, identifier s9134); siABL1 (ThermoFisher cat# 4390824, identifier s864); siRPL3 (ThermoFisher cat# 4392420, identifier s12142); siNAT10-1 (ThermoFisher cat# 4392420, identifier s30491); siNAT10-2 (ThermoFisher cat# 4392420, identifier s30492).
Lentivirus: Lentiviral shRNA particles were prepared as previously described 19, 20 . Viral titers were determined using Takara Lenti-X™ GoStix™ as per the manufacturer protocol. ShRNA constructs used: shCon/Con1 (SHC216, sequence 5'-CGTGATCTTCACCGACAAGAT-3'); shCon2 (SHC204, sequence 5'-CGTGATCTTCACCGACAAGAT-3'); shEV (SHC201-no insert); shLIN28B1/B1 (TRCN0000144508, sequence 5'-CCTGTTTAGGAAGTGAAAGAA-3'); shLIN28B2/B2 (TRCN0000122599, sequence 5'-GCCTTGAGTCAATACGGGTAA-3'); shLIN28B3/B3 (TRCN0000122191, sequence 5'-GCAGGCATAATAAGCAAGTTA-3'); shNAT10-1 (TRCN0000296411, sequence 5'-TTGCTGTTCACCCAGATTATC-3'); shNAT10-2 (TRCN0000035702, sequence 5'-CGCAAAGTTGTGAAGCTATTT-3'). CRISPR/Cas9 constructs used: V2-Cas9 (lentiCRISPRv2, Addgene plasmid #52961), V2-GFP1 was created by cloning eGFP sgRNA sequence 5'-GGGCGAGGAGCTGTTCACCG-3' into the lentiCRISPRv2 vector. V2-GFP2 was created by cloning eGFP sgRNA sequence 5'-GAGCTGGACGGCGACGTAAA-3' into the lentiCRISPRv2 vector. LentiCRISPRv2 was a gift from F. Zhang 19, 20 .
Western Blotting: Western blots were performed with antibodies against LIN28B (Cell Signaling 4196), MYCN (Santa Cruz Biotechnology sc-53993), NAT10 (Proteintech 13365-1-AP), β-Tubulin (Cell Signaling 2146), and β-Actin (Santa Cruz Biotechnology sc-8342).
Reanalysis of publicly available datasets:
We reanalyzed publicly available microarray datasets. The accession numbers for theses studies are GSE46708 and GSE74622. For GSE46708, we downloaded processed data from GEO. For GSE74622, we used the R packages oligo and the annotation package pd.hugene.2.0.st to process raw .CEL files. Differential expression analysis was performed using the R package limma. We used the R packages clusterProfiler and ReactomePA for gene ontology enrichment analysis. For GSE46708, we used genes with log2 fold changes > 0.5 or < -0.5 for gene ontology analysis. For GSE74622, we used genes with log2 fold changes > 0.25 or < -0.25 for gene ontology analysis. Clustering and heat map visualization were performed the pheatmap package.
Literature analysis:
We downloaded xml files from ftp://ftp.ncbi.nlm.nih.gov/pub/pmc and wrote customized scripts to parse these xml files and query combinations of keywords throughout each manuscript. These scripts are available from the authors upon reasonable request. shCon shB1
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Supplemental Figure 7 Supplemental Figure 8 -Titer lentiviral supernatants. Carefully titrate viral dose down to as low an MOI as possible to effectively knockdown the gene-of-interest.
-Use an empty vector and at least one nontargeting shRNA control, especially when performing RNA-seq or other bioinformatics.
-Rescue the effect of shRNA knockdown with gene-of-interest re-introduction.
-Validate shRNA results by siRNA knockdown or CRISPR/Cas9 mediated knockout
